鼻咽癌中PMS2基因启动子甲基化导致的失活
该研究检测了54例鼻咽癌组织、16例正常鼻咽上皮、5株鼻咽癌细胞系和1株正常鼻咽上皮细胞系中PMS2启动子甲基化及其mRNA和蛋白表达。鼻咽癌组织甲基化率为63%(34/54),显著高于正常鼻咽上皮的0/16(P<0.001),甲基化组织的PMS2 mRNA和蛋白表达显著低于未甲基化组织(P<0.001),去甲基化处理后CNE1和CNE2细胞PMS2 mRNA表达恢复。结论认为PMS2启动子甲基化介导的失活参与鼻咽癌发生发展,PMS2可能是候选抑癌基因。
要点
- 鼻咽癌组织PMS2启动子甲基化率为63%(34/54),正常鼻咽上皮为0/16(P<0.001)。
- 甲基化鼻咽癌组织的PMS2 mRNA和蛋白表达显著低于未甲基化组织(P<0.001)。
- PMS2 mRNA和蛋白表达与年龄、性别、TNM分期、病理类型及淋巴结转移无显著相关(P>0.05)。
核心结论
- PMS2基因启动子甲基化介导的失活参与鼻咽癌的发生发展。
- PMS2可能是治疗PMS2启动子甲基化失活患者的候选抑癌基因。
研究设计与样本
- 收集54例鼻咽癌组织、16例正常鼻咽上皮、5株鼻咽癌细胞系(CNE1、CNE2、TWO3、HNE1和HONE1)和1株正常鼻咽上皮细胞系(NP69)。
- 采用甲基化特异性PCR(MSP)检测PMS2启动子甲基化,半定量逆转录PCR(qRT-PCR)检测mRNA表达,免疫组化(IHC)检测PMS2蛋白表达。
- 用甲基转移酶抑制剂5-氮杂-2-脱氧胞苷处理CNE1和CNE2细胞,qRT-PCR分析处理前后PMS2 mRNA表达。
- 分析甲基化与去甲基化对PMS2 mRNA表达的影响,以及PMS2 mRNA和蛋白表达与鼻咽癌临床病理特征的关系。
主要发现
- 5株鼻咽癌细胞系均检测到PMS2基因甲基化,正常鼻咽上皮细胞NP69未检测到。
- 鼻咽癌组织PMS2基因甲基化率为63%(34/54),显著高于正常鼻咽上皮的0/16(P<0.001)。
- 54例鼻咽癌组织中PMS2 mRNA和蛋白表达水平显著低于16例正常鼻咽上皮组织(P<0.001)。
- 34例甲基化鼻咽癌组织中PMS2 mRNA和蛋白表达显著低于20例未甲基化鼻咽癌组织(P<0.001)。
- 5-氮杂-2-脱氧胞苷处理后,CNE1和CNE2细胞中PMS2 mRNA表达恢复。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the inactivation of PMS2 gene mediated by promoter methylation and its regulatory mechanism in nasopharyngeal carcinoma (NPC). Methods: Fifty-four NPC tissues, 16 normal nasopharyngeal epithelia (NNE), 5 NPC cell lines (CNE1, CNE2, TWO3, HNE1 and HONE1) and 1 normal nasopharyngeal epithelial cell line (NP69) were collected.Methylation-specific PCR (MSP) was used to detect the PMS2 promoter methylation, semi-quantitative reverse transcription PCR (qRT-PCR) was applied to determine its mRNA expression, and immunohistochemistry (IHC) was used to detect the protein expression of PMS2. The expressions of PMS2 mRNA in CNE1 and CNE2 cells before and after treated with methyltransferase inhibitor 5-aza-2-deoxycytidine were analyzed by qRT-PCR. The impact of methylation and demethylation on the mRNA expression of PMS2, and the association of mRNA and protein expression of PMS2 with clinicopathological features of nasopharyngeal cancer were analyzed. Results: Methylation of PMS2 gene was detected in all of the five NPC cell lines, but not in normal nasopharyngeal epithelial NP69 cells. The methylation rate of PMS2 gene in NPC tissues was 63% (34/54), significantly higher than that of the normal nasopharyngeal epithelia (0/16, P<0.001). The expression levels of PMS2 mRNA and protein were significantly down-regulated in the 54 NPC tissues when compared with those in the 16 NNE tissues (P<0.001), and were also significantly lower in the 34 methylated NPC tissues than those in the 20 unmethylated NPC tissues (P<0.001). After treatment with 5-aza-2-deoxycytidine, the expression of PMS2 mRNA was restored in the CNE1 and CNE2 cells.However, the expressions of PMS2 mRNA and protein were not significantly correlated with patients' age, gender, TNM stage, histopathologic type or lymph node metastasis (P>0.05 for all). Conclusions: Promoter methylation-mediated inactivation of PMS2 gene participates in carcinogenesis and development of NPC. PMS2 may be a candidate tumor suppressor in the treatment for patients with inactivation of PMS2 promoter methylation.
引用
- Ni HF, Jiang B, Zhou Z, et al. [Inactivation of PMS2 gene by promoter methylation in nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998438. doi:10.3760/cma.j.issn.0253-3766.2016.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。